EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • May 14th, 2021 • Roivant Sciences Ltd. • New York
THIS EMPLOYMENT AGREEMENT (the “Agreement”) is hereby entered into as of May 14, 2021 (the “Effective Date”), by and between Roivant Sciences, Inc., a Delaware corporation (the “Company”), and Benjamin Zimmer, an individual (“Executive”) (hereinafter collectively referred to as the “Parties”).
ASSET PURCHASE AGREEMENT by and among GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LTD., GLAXO GROUP LIMITED, AND DERMAVANT SCIENCES GMBH July 10, 2018Asset Purchase Agreement • May 14th, 2021 • Roivant Sciences Ltd. • Delaware
This Asset Purchase Agreement (this “Agreement”) is made and dated as of July 10, 2018, by and among Glaxo Group Limited, a company incorporated under the laws of England and Wales (“GGL”), GlaxoSmithKline Intellectual Property Development Ltd., a company incorporated under the laws of England and Wales (“GIPD,” and together with GGL, “Seller Parties”) and Dermavant Sciences GmbH, a company incorporated under the laws of Switzerland (“Buyer”). Seller Parties and Buyer may each be referred to herein individually as a “Party” and collectively as the “Parties.”
FIRST AMENDMENT TO FUNDING AGREEMENTFunding Agreement • May 14th, 2021 • Roivant Sciences Ltd.
This First Amendment to Funding Agreement (this “Amendment”) is made and entered into as of October 11, 2018 (the “First Amendment Effective Date”), by and between Dermavant Sciences GmbH, a company organized under the laws of Switzerland (“Dermavant”), and NovaQuest Co-Investment Fund VIII, L.P. a limited partnership organized under the laws of Delaware, with a place of business at 4208 Six Forks Road, Suite 920 Raleigh, NC 27609 (“NovaQuest”).
ContractClinical Manufacturing and Supply Agreement • May 14th, 2021 • Roivant Sciences Ltd. • Delaware
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE DERMAVANT SCIENCES LTD. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO DERMAVANT SCIENCES LTD. IF PUBLICLY DISCLOSED.
ContractCommercial Manufacturing and Supply Agreement • May 14th, 2021 • Roivant Sciences Ltd. • Delaware
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE DERMAVANT SCIENCES LTD. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO DERMAVANT SCIENCES LTD. IF PUBLICLY DISCLOSED.
FUNDING AGREEMENTFunding Agreement • May 14th, 2021 • Roivant Sciences Ltd. • New York
This Funding Agreement (this “Agreement”) is entered into as of July 10, 2018 (the “Effective Date”), between Dermavant Sciences GmbH, a company organized under the laws of Switzerland (“Dermavant”), and NovaQuest Co-Investment Fund VIII, L.P. a limited partnership organized under the laws of Delaware, with a place of business at 4208 Six Forks Road, Suite 920 Raleigh, NC 27609 (“NovaQuest”). Dermavant and NovaQuest are each referred to herein by name or, individually, as a “Party” or, collectively, as “Parties.”
COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • May 14th, 2021 • Roivant Sciences Ltd. • New York
THIS COLLABORATION AND LICENSE AGREEMENT (“Agreement”) is entered into as of January 15, 2020 (the “Effective Date”), by and between Dermavant Sciences GmbH, a company incorporated under the laws of Switzerland, and having an address at [***] (“Dermavant”) and Japan Tobacco Inc., a company incorporated under the laws of Japan and having its principal place of business at [***] (“Licensee”).
ASSET PURCHASE AGREEMENTAsset Purchase Agreement • May 14th, 2021 • Roivant Sciences Ltd. • New York
This Asset Purchase Agreement (the “Agreement”) is entered into as of this 29th day of May, 2012 (the “Effective Date”), by and between Glaxo Group Limited, a company incorporated under the laws of England and Wales with offices at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN under company number 00305979 (“GSK”) and Welichem Biotech Inc., a company incorporated under the laws of British Columbia with offices at Suite 316, 4475 Wayburne Drive, Burnaby, British Columbia, V5G 3L1, Canada (“Welichem”). GSK and Welichem may be referred to herein separately as a “Party” or together as the “Parties.”
AMENDMENT NUMBER ONE TO ASSET PURCHASE AGREEMENTAsset Purchase Agreement • May 14th, 2021 • Roivant Sciences Ltd.
THIS AMENDMENT NUMBER ONE (this “Amendment”) is entered into as of the 31 day of August 2012 (the “Effective Date”) by and between: (i) Glaxo Group Limited a company incorporated under the laws of England and Wales having its registered office at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 ONN (“GSK”), and (ii) Welichem Biotech, Inc., a company incorporated under the laws of British Columbia, V5G 3Ll, Canada (“Welichem”) (together, the “Parties”).
May 14, 2021 Vivek Ramaswamy Via Email Re: Amended and Restated Employment Agreement Dear Vivek:Employment Agreement • May 14th, 2021 • Roivant Sciences Ltd. • New York
This letter agreement (this “Agreement”), memorializes our mutual understanding regarding your continued employment with Roivant Sciences, Inc., a Delaware corporation (the “Company”). This Agreement amends and restates, effective as of May 14, 2021 (the “Effective Date”), your prior employment agreement with the Company, dated March 4, 2016 (the “Prior Agreement”). Reference is made in this Agreement to the letter agreement between you and the Company, dated March 30, 2021 (the “Letter Agreement”).
